1. The central blood pressure effects of the enkephalin analogue, D-Ala'-Met-enkephalin were investigated in normotensive rats and in spontaneously hypertensive rats.
Introduction
The regional distribution of enkephalins in the brain has been shown to be partly identical with brain nuclei involved in cardiovascular regulation [ l , 21. This indicates that opioid peptides could play a role in central mechanisms of blood pressure control. Some investigators have reported that centrally applied opiates or opioid peptides increase arterial blood pressure [ 3-5 J but others have observed blood pressure de-, creases 16-91. These results were obtained partly in conscious and partly in anaesthetized animals.
In the present experiments, we studied the central blood pressure responses to DAla*-Metenkephalin (DAME) in both conscious and a-chloralose-anaesthetized animals. The synthetic long-lived enkephalin analogue was injected intracerebroventricularly (i.c.v.) , into the lateral brain ventricle, in normotensive and spontaneously hypertensive rats. The specificity of the blood pressure effects was tested by means of the opiate receptor antagonists naloxone and diprenorphine. These substances were also used to inhibit endogenous enkephalis.
Materials and methods
Male Wistar rats weighing 200-250 g were housed individually under identical conditions of room temperature and humidity. Adult male and female spontaneously hypertensive rats of the stroke-prone strain (SHRSP), bred in Heidelberg since 1975, and age-and sex-matched normo-tensive Wistar-Kyoto (WKY) rats were used. A polyethylene cannula (PP 20) was stereotaxically implanted into the lateral brain ventricle for the intracerebroventricular injections at least 1 week before the acute experiment. The following co-ordinates were used: 0.5 mm posterior and 1.3 mm lateral from the bregma and 5.0 mm ventral from the surface of the skull. One day before the experiment, a polyethylene catheter (PP 10 connected to PP 50) was placed in the abdominal aorta through the femoral artery. The catheter was tunnelled under the skin and exteriorized at the scruff of the neck. Arterial blood pressure and heart rate were recorded through the arterial catheter on to a Gould Brush 2400 apparatus, a Statham P23 Db pressure transducer and a Gould Brush computer being used. Measurements in conscious rats were made while the animals were freely moving in a wooden box (20 cm x 12 cm x 11 cm). Measurements in anaesthetized rats were performed 1-2 h after intraperitoneal injection of a-chloralose at a dose of 50 mg/kg. Additional injections of ac-chloralose were given if necessary.
The intracerebroventricular doses of DAME were 1.7, 17 and 170 nmol in a maximum total volume of 10 pl injected with a Hamilton microsyringe. Each animal was given only one dose a day. In order to test the specificity of the enkephalin-induced cardiovascular responses, the opiate receptor antagonists naloxone and diprenorphine were injected i.c.v. at doses of 10-500 nmol, 3-5 min before the DAME injection (170 nmol). Controls received 0.9% sodium chloride solution (saline) instead of the antagonists.
The opiate receptor antagonist diprenorphine was injected i.c.v. into SHRSP and WKY at doses of 10 and 100 nmol to investigate the effect of central blockade of endogenous opioid peptides.
Results are given as means f SEM. To evaluate statistical differences, Student's paired and unpaired t-tests were used. Statistical significance was accepted at the 5% level.
D-Ala*-Met-enkephalin (lot no. B 053) was purchased from Bioproduct (Belgium). Naloxone hydrochloride was obtained from Endo Laboratories Inc. (New York, U.S.A.). Diprenorphine hydrochloride was a gift from Reckitt and Colman (Kingston upon Hull, U.K.).
Results

Intracerebroventricular injections of DAME
In conscious rats, injections of 1.7, 17 and 170 nmol of DAME into the lateral brain ventricle produced dose-dependent blood pressure increases of 5.3 f 1.8, 10.5 f 2.8 and 15.3 ? 3.0 mmHg respectively. An initial short peak was followed by a second long-lasting increase which had its maximum 15-20 min after the injection, and lasted about 30 min at the highest dose injected. Behavioural changes were characterized by loss of spontaneous mobility without catatonia and lasted more than 1 h at the dose of 170 nmol.
In cc-chloralose-anaesthetized rats, the same doses of DAME caused dose-dependent blood pressure falls of -8.9 f 1.9, -11.1 f 5.2 and -19.8 f 8.4 mmHg. The blood pressure decreases were characterized by a long-lasting plateau phase after the initial fast blood pressure drop. Maximum decreases were seen at 8-10 min. Blood pressure returned to its basal level about 1 h after injection.
Intracerebroventricular injections of DAME after pretreatment with opiate receptor antagonists
Diprenorphine and naloxone were injected i.c.v. 3-5 min before 170 nmol of DAME. In diprenorphine-treated conscious animals the blood pressor responses to 170 nmol of DAME were reversed to blood pressure falls. Pretreatment with naloxone produced a similar blockade of the central effects of DAME in conscious rats.
In echloralose-anaesthetized rats, the depressor responses to DAME given i.c.v. were blunted with the lowest dose and completely prevented with the highest dose of diprenorphine. In contrast, pretreatment with 10 and 100 nmol of naloxone did not counteract the depressor responses to DAME given i.c.v.
Intraventricular injections of DAME and opiate antagonists in spontaneously hypertensive rats
Conscious SHRSP showed markedly enhanced pressor responses to DAME injected i.c.v. when compared with WKY rat controls. At 170 nmol the respective blood pressure changes were 24.6 f 3.2 vs 12.0 f 3.2 mmHg ( P < 0.05).
The opiate receptor antagonist diprenorphine given alone i.c.v. at a dose of 100 nmol produced an initial short blood pressure increase followed by a long-lasting blood pressure fall; this was markedly greater in SHRSP than in WKY rats (-18.3 ? 3.0 vs 6.2 k 2.0 mmHg; P < 0.01) (Fig. 1) . After a smaller dose of diprenorphine (10 nmol i.c.v.) blood pressure showed a slight fall in SHRSP (-4.3 f 1.4 mmHg) without the initial increase. 
Discussion
Our results demonstrate that central administration of DAME produces blood pressure increases as well as blood pressure decreases depending on whether the animals were conscious or anaesthetized. Thus the central blood pressure effects of enkephalins clearly depend on the state of consciousness. This could possibly help to explain some of the discrepancies in the literature concerning the central cardiovascular effects of morphinomimetic substances [4, . The fact that both opiate receptor antagonists, naloxone and diprenorphine, counteracted the central pressor responses to DAME in conscious animals suggests that this opioid peptide produces its effects through stimulation of specific opiate receptors in the brain. In a-chloraloseanaesthetized rats, however, the depressor responses to DAME injected i.c.v. could only be prevented by diprenorphine and not by naloxone. These findings suggest an involvement of different subtypes of opiate receptors in mediating the central cardiovascular actions of opioid peptides, the exact nature of which remains to be estabstance P [151. An involvement of these peptides in the maintenance of high blood pressure in SHRSP has been claimed from biochemical and pharmacological evidence [ 161. Thus the inhibition of brain angiotensin-converting enzyme with captopril 1171 or blockade of central angiotensin receptors with saralasin and other angiotensin antagonists [181 has led to blood pressure falls in SHRSP but not in normotensive rats.
Our finding reported here of a marked reduction of blood pressure in SHRSP after the central administration of diprenorphine provides further evidence that not only a central inhibition of the renin-angiotensin system but also the blockade of brain opiate receptors can lower blood pressure in this type of experimental hypertension. This raises the possibility of opioid peptides in the brain contributing to the maintenance of elevated blood pressure in SHRSP in addition to the brain renin-angiotensin system, and lends further support to the concept of central peptidergic stimulation being a possible pathogenetic factor in hypertension [ 161. lished [4, 11-131. In the SHRSP, a supersensitivity to centrally administered DAME was observed. Similar Acknowledgments results have been reported previously with leucine-enkephalin and methionine-enkephalin [41 These studies were supported by the Deutsche but also with other non-opioid brain peptides Forschungsgemeinschaft within the SFB 90 such as angiotensin [ 141, bradykinin and subCardiovaskulares System.
